Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with…
Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…
Antipsychotics are the standard of care for treating schizophrenia, with oral atypical antipsychotics (e.g., olanzapine, risperidone) experiencing preferential use. Because of the heterogeneity of…
Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…
The treatment landscape for major depressive disorder (MDD), consists of numerous safe and effective treatment options, many of which are available as inexpensive generics. Therapies to treat MDD…
Atrial fibrillation is the most commonly encountered, sustained cardiac arrhythmia in clinical practice. The fixed-dose, nonmonitored NOACs for stroke prevention, which offer much-improved efficacy…
Market Outlook Elevated serum potassium, commonly known as hyperkalemia, is a condition common in patients with decreased renal function and heart failure and is often exacerbated by those…
The standard of care in AHF has remained largely unchanged since the 1970s, resulting in a highly genericized market. AHF patients continue to experience high rates of mortality and morbidity…
Parkinson’s disease (PD) is the second-most common neurodegenerative disorder that, according to DRG epidemiology, afflicts more than 1.5 million people in the EU5. Although PD treatment has been…
The diabetic nephropathy (DN) market is poised to expand rapidly over the next decade as late-stage therapies reach the G7 markets. These agents represent the first potential disease-modifying…
NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust…
Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on this space are…
Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have…
Hyperkalemia, a condition of elevated serum potassium, arises from disturbances to potassium homeostasis within the body. Among key populations, including patients with kidney disorders and/or HF,…
Most patients with chronic obstructive pulmonary disease (COPD) in the five European countries under study receive treatment shortly after diagnosis. The progressive nature of the disease results…